| http://www.w3.org/ns/prov#value | - He is a sought-after speaker and panel participant on regulatory and quality issues affecting the pharmaceutical industry and has presented on topics including drug development, 505(b)(2) NDAs, GxPs, compliance, outsourcing, stability, PAIs, interactions with regulatory agencies and controlled substances.
|
